California is currently home to 5605 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Automated Robotic TCD in Traumatic Brain Injury
Recruiting
This study's objective is to determine the safety, feasibility and efficacy of prolonged automated robotic TCD monitoring in critically ill patients with severe TBI across multiple clinical sites with varying levels of TCD availability and experience
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: University of California, Davis, Davis, California
Conditions: Brain Injuries, Traumatic
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Recruiting
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/23/2025
Locations: Research Site, Duarte, California
Conditions: Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer
Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis
Recruiting
The purpose of this pilot study to examine the feasibility and acceptability of simvastatin in adults with Recurrent Acute Pancreatitis (RAP) and Chronic Pancreatitis (CP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/23/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Recurrent Acute Pancreatitis, Chronic Pancreatitis
Incomplete Cervical SCI Without Instability
Recruiting
A multicenter, international, prospective, observational case series patient cohort with incomplete cervical SCI without instability will be enrolled to obtain information and data that could inform the feasibility of administering a set of additional core and optional outcome assessments in cervical SCI patients to capture the aspects of neurologic impairment. Baseline, intraoperative, and postoperative characteristics, including demographics, injury details, treatment details, neurological ass... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/23/2025
Locations: San Francisco General Hospital, San Francisco, California
Conditions: Cervical Spinal Cord Injury
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Recruiting
The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Surgical Site Infection
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Recruiting
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
07/23/2025
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Recruiting
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. Severe bleeding events require VWF concentrates administered solely through intravenous access. Emicizumab (Hemlibra) is a monoclonal bispecific antibody developed to bind activated FIX and FX and mimic FVIII cofactor functionality. Hemlibra is administered via subcutaneous in... Read More
Gender:
ALL
Ages:
Between 0 years and 90 years
Trial Updated:
07/23/2025
Locations: The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD), Orange, California
Conditions: Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Recruiting
This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD19 and CD20, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: City of Hope, Duarte, California
Conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/23/2025
Locations: Research Site, La Jolla, California
Conditions: Advanced Solid Malignancies
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
Recruiting
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed. XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 pa... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/23/2025
Locations: UCLA Doheny Eye Center /ID# 227587, Pasadena, California
Conditions: Open-Angle Glaucoma
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Research Site, Fountain Valley, California
Conditions: Non-Small Cell Lung Cancer
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
07/23/2025
Locations: Lucile Packard Children's Hospital Stanford, Palo Alto, California
Conditions: Partial Epilepsy